This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Laster Scrutinizes Strike Suits in Theragenics Litigation

NEW YORK (The Deal) -- J. Travis Laster is a bold judge, and the Delaware vice chancellor was at his most aggressive in a Feb. 21 order where he asked very probing questions of the shareholders and lawyers who brought a fiduciary duty lawsuit challenging the $68 million sale of Theragenics to Juniper Investment. Several lawyers not involved in the matter say they've never seen anything like Laster's order, which may be the latest salvo in the Delaware courts' effort to rein in the shareholder litigation that follows virtually every merger or acquisition of a Delaware public company.

As is common, Theragenics shareholders sued to challenge the deal soon after it was announced Aug. 5 on the grounds that in approving the transaction the company's directors had violated their fiduciary duties. The parties agreed to a settlement, which requires judicial approval because the matter is styled as an action on behalf of the entire class of Theragenics shareholders, who approved the deal. Over 96% of the shares cast - a total of 64% of the total float - were voted in favor of the deal, which closed Oct. 29. Theragenics was a surgical device company.

On Friday, Laster issued an order in which he scheduled a May 5 hearing to approve the settlement and the attorneys' fees that the shareholders' counsel at Rigrodsky & Long PA are seeking. Most of the order was boilerplate, but one portion was not. Laster required Rigrodsky to answer several questions that reflect a deep skepticism about the conduct of the Theragenics litigation and similar cases. His order could indicate he's considering a reduction in how much Rigrodsky is paid.

The judge did ask similar questions in an order consolidating the shareholder litigation arising from the Activision Blizzard's (ATVI - Get Report) buying back a control stake from Vivendi last year. But the answers there were meant to help Laster appoint lead counsel for the shareholder plaintiffs and that case isn't much help in pointing to how Laster's plans to use the information in the Theragenics proceeding.

Critics of suits like Theragenics' - a group that occasionally includes the Delaware judges who hear such matters - believe that the shareholder plaintiffs are mere figureheads and that their counsel choose to bring the cases and determine when to settle them. Shareholders themselves almost never receive additional payment. Instead, the companies agree to disclose additional facts about the merger negotiations or the way bankers arrived at a valuation for the company and as part of the settlement pay shareholders' counsel a fee that's generally hundreds of thousands of dollars per case.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
ATVI $23.05 0.00%
CVX $109.04 0.00%
AAPL $128.95 0.00%
FB $78.99 0.00%
GOOG $537.90 0.00%

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs